Drug Trial Radar · NCT07582133
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Jul 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.
Conditions
- Primary IgA Nephropathy
Interventions
HRS-5965 CapsulesDrug
HRS-5965 Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events (AEs) throughout the study;Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.